Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network

Clinical Infectious Diseases

Volumn 46, Issue 11, 2008, Pages 1738-1740

  Winthrop, Kevin L ^a   Yamashita, S ^a   Beekmann, S E ^b   Polgreen, P M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFECTIVE AGENT; ETANERCEPT; INFLIXIMAB; ISONIAZID; METHOTREXATE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; DEMOGRAPHY; DRUG APPROVAL; DRUG TOLERABILITY; HEALTH SURVEY; HISTOPLASMOSIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MYCOBACTERIUM; PRIORITY JOURNAL; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; TUBERCULOSIS;

BIOLOGICAL THERAPY; DATA COLLECTION; HUMANS; INFORMATION SERVICES; MYCOBACTERIUM INFECTIONS; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43949117120     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587989     Document Type: Article

References (11)

1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
2. van Ingen J, Boeree M, Janssen M, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007; 3:414-9.
3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5 (erratum: Clin Infect Dis 2004; 39:1254-5).
4. Winthrop KL, Seigel JN, Jereb J, Taylor Z, Iademarco MF. TB associated with therapy against tumor necrosis factor a. Arthritis Rheum 2005; 52:2968-74.
5. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent TB infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72.
6. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005; 9:1057-8.
7. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated TB. AIDS 2004; 18:257-64.
8. Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium TB. J Immunol 2007; 178:7222-34.
9. Ulrichs T, Kosmiadi GA, Trusov V, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004; 204:217-28.
10. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-76.
11. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of TB. Arthritis Rheum 2006; 55:19-26.